Last updated on February 2018

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer


Brief description of study

Breast cancer is the most common form of cancer among women. For patients candidated for adjuvant chemotherapy and endocrine therapy the optimal timing for their has not been clearly defined yet.

Detailed Study Description

Breast cancer is the most common form of cancer among women in North America, Europe and Latin America. Because nearly 80% of breast cancers are endocrine-responsive tumors, the majority of patients candidates for adjuvant chemotherapy (CT) are also candidates for endocrine therapy (ET). The optimal timing (i.e. concomitant vs sequential administration) for the integration of these two treatments has not been clearly defined yet.

In patients with hormone receptor positive early stage breast cancer who are candidates to adjuvant chemotherapy and endocrine therapy, the optimal timing for the integration of these two treatment modalities has not been clearly defined yet.

Clinical Study Identifier: NCT02918084

Contact Investigators or Research Sites near you

Start Over

Evaristo Maiello, MD

IRCCS `Casa Sollievo della Sofferenza`
San Giovanni Rotondo, Italy
  Connect »